Image

Speech Entrainment for Aphasia Recovery

Speech Entrainment for Aphasia Recovery

Not Recruiting
21-81 years
All
Phase 2

Powered by AI

Overview

After a stroke, many people experience a language impairment called aphasia. One of the most debilitating types of aphasia is non-fluent aphasia. Non-fluent aphasia is defined by significantly reduced speech production, with the speaker producing only a few words or even less. Speech entrainment therapy (SET) is a treatment that has been shown to increase fluency in people with non-fluent aphasia. The study looks to define the best dose of SET that leads to sustained improvements in spontaneous speech production.

Participants who are eligible will undergo baseline language testing, an MRI, and will be randomized into one of 4 treatment groups: SET for 3 weeks, SET for 4.5 weeks, SET for 6 weeks, and no treatment (control group).

Eligibility

Inclusion Criteria

  • Aphasia as a result of a left hemisphere ischemic or hemorrhagic stroke (WAB-R Aphasia Quotient <93.8).
  • Presence of left hemisphere stroke in clinical imaging (CT/MRI) and NIHSS
  • Participants must have spoken English as their primary language.
  • 21-81 years old
  • Pre-stroke modified Rankin Scale (mRS)= 2 or less
  • Post-stroke mRS= 4 or less.
  • At least 6 months post-stroke.
  • Non-fluent aphasia (WAB-R Comprehension score >4 and WAB-R Fluency score <6).
  • Technological compatibility (to be determined by clinical judgment of SLP)

Exclusion Criteria

  • History of chronic neurological or psychiatric diseases (excluding migraines, depression, or post-stroke epilepsy). Self-reported history of learning disability.
  • Severe dysarthria (determined via SLP clinical judgment from spontaneous speech tasks on the ASRS 3.0).
  • Global aphasia.
  • History of right-hemisphere strokes or brain stem/cerebellar strokes with persistent deficits (as evidenced by MRI/CT and NIHSS).
  • Uncorrectable hearing as determined by the SLP's clinical judgment.
  • Uncorrectable vision.
  • Contraindications to MRI or inability to complete the MRI scanning session.
  • Women who are pregnant.

Study details
    Aphasia
    Aphasia Non Fluent
    Stroke

NCT04364854

Medical University of South Carolina

12 December 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.